Early Outcomes of Ruxolitinib in the Treatment of Steroid Refractory Graft-versus-host Disease on Liver Transplant Recipients

Transplantation. 2020 Aug;104(8):e247. doi: 10.1097/TP.0000000000003252.

Authors

Sunilkumar Kakadia¹, Holly Trotta², Leslie Kurczek², Lyle Burdine², Muthu Veeraputhiran¹, Emmanouil Giorgakis²

Affiliations

¹ Department of Medicine, Hematology and Oncology, University of Arkansas for Medical Sciences, Little Rock, AR.
² Department of Surgery, Solid Organ Transplantation, University of Arkansas for Medical Sciences, Little Rock, AR.

PMID: 32732859
DOI: 10.1097/TP.0000000000003252

No abstract available

Publication types

Comment

MeSH terms

Graft vs Host Disease*
Hematopoietic Stem Cell Transplantation*
Humans
Liver Transplantation*
Nitriles
Pyrazoles
Pyrimidines

Substances

Nitriles
Pyrazoles
Pyrimidines
ruxolitinib